Literature DB >> 2203397

Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.

G Melandri1, A Branzi, F Semprini, V Cervi, N Galiè, B Magnani.   

Abstract

Because paradoxical increase in thrombin activity was reported after the administration of streptokinase in patients with acute myocardial infarction the velocity of reperfusion and degree of myocardial damage were studied when heparin was infused during rather than after streptokinase infusion. Thirty seven consecutive patients with acute myocardial infarction were randomised to receive intravenous heparin during (group 1, n = 18) or after (group 2, n = 19) streptokinase (1.5 megaunits over 60 minutes). Markers of reperfusion were monitored every 15 minutes for 3 hours. The serum concentration of creatine kinase was measured every 2 hours. The two groups were similar in terms of age and sex distribution, infarct site, time to treatment, and baseline myocardial ischaemia. Patients in group 1 had a significantly shorter mean (SD) reperfusion time (57 (35) minutes v 101 (47)). From 60 to 120 minutes after randomisation there were significant differences in ST segment elevation between the groups. Serum creatine kinase MB peaked earlier (8 (2) hours) in group 1 than in group 2 (10 (4) hours). The peak concentration was significantly lower in group 1 (87 (47) mU/ml) than in group 2 (134 (96) mU/ml) and infarcts were smaller (25.2 (9.8) gram equivalents/m2) in group 1 than in group 2 (35.1 (10.2) gram equivalents/m2). Simultaneous infusion of heparin and streptokinase speeds up the appearance of signs of reperfusion and reduces infarct size.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2203397      PMCID: PMC1024350          DOI: 10.1136/hrt.64.2.118

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  23 in total

1.  Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: relationships to coronary pathoanatomy, risk factors, and clinical manifestations.

Authors:  G G Neri Serneri; G F Gensini; R Abbate; C Mugnaini; S Favilla; C Brunelli; S Chierchia; O Parodi
Journal:  Am Heart J       Date:  1981-02       Impact factor: 4.749

2.  Estimation of infarct size from serum MB creatine phosphokinase activity: Applications and limitations.

Authors:  B E Sobel; R Roberts; K B Larson
Journal:  Am J Cardiol       Date:  1976-03-31       Impact factor: 2.778

3.  Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction.

Authors:  J M Gore; R Roberts; S P Ball; A Montero; R J Goldberg; J E Dalen
Journal:  Am J Cardiol       Date:  1987-06-01       Impact factor: 2.778

4.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.

Authors:  P R Eisenberg; L A Sherman; A S Jaffe
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

5.  Effects of early intracoronary streptokinase on infarct size estimated from cumulative enzyme release and on enzyme release rate: a randomized trial of 533 patients with acute myocardial infarction.

Authors:  A van der Laarse; F Vermeer; W T Hermens; G M Willems; K de Neef; M L Simoons; P W Serruys; J Res; F W Verheugt; X H Krauss
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

6.  Intravenous streptokinase in evolving acute myocardial infarction.

Authors:  W Ganz; I Geft; P K Shah; A S Lew; L Rodriguez; T Weiss; J Maddahi; D S Berman; Y Charuzi; H J Swan
Journal:  Am J Cardiol       Date:  1984-05-01       Impact factor: 2.778

7.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells.

Authors:  T D Gelehrter; R Sznycer-Laszuk
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

8.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; M Takayama; A Maslowski; N M Bass; J A Ormiston; T Whitlock
Journal:  N Engl J Med       Date:  1987-10-01       Impact factor: 91.245

9.  Nonsurgical reperfusion in evolving myocardial infarction.

Authors:  W Ganz; I Geft; J Maddahi; D Berman; Y Charuzi; P K Shah; H J Swan
Journal:  J Am Coll Cardiol       Date:  1983-05       Impact factor: 24.094

10.  Noninvasive detection of coronary artery patency using continuous ST-segment monitoring.

Authors:  M W Krucoff; C E Green; L F Satler; F C Miller; R S Pallas; K M Kent; A A Del Negro; D L Pearle; R D Fletcher; C E Rackley
Journal:  Am J Cardiol       Date:  1986-04-15       Impact factor: 2.778

View more
  4 in total

1.  Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.